The Fundamental Role of BARD1 Mutations and Their Applications as a Prognostic Biomarker for Cancer Treatment
Authors:
- Yousef M. HawsawiYHYousef M. Hawsawi
- Anwar ShamsASAnwar Shams
Open Access
- 18 January 2023
- book chapter
- Published by IntechOpen
Abstract
BRCA1-associated RING domain 1 (BARD1) constitutes a heterodimeric complex with BRAC1 that triggers several essential biological functions that regulate gene transcription and DNA double-stranded break repair mechanism. BARD1 gene was discovered in 1996 to interact with BRCA1 directly and encodes a 777-aa protein. Interestingly, the BARD1 has a dual role in breast cancer development and progression. It acts as a tumor suppressor and oncogene; therefore, it is included on panels of clinical genes as a prognostic marker. Structurally, BARD1 has homologous domains to BRCA1 that aid their heterodimer interaction to inhibit the progression of different cancers, including breast and ovarian cancers. In addition to the BRCA1-independent pathway, other pathways are involved in tumor suppression, such as the TP53-dependent apoptotic signaling pathway. However, there are abundant BARD1 isoforms that are different from full-length BARD1 due to nonsense and frameshift mutations and deletions associated with susceptibility to cancer, such as neuroblastoma, lung cancer, cervical cancer, and breast cancer. In the current chapter, we shed light on the spectrum of BARD1 full-length genes and isoform mutations and their associated risk with breast cancer. The chapter also highlights the role of BARD1 as an oncogene in breast cancer patients and its uses as a prognostic biomarker for cancer susceptibility testing and treatmentKeywords
This publication has 94 references indexed in Scilit:
- Common Variation atBARD1Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and OncogenicityCancer Research, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- BARD1 Expression Predicts Outcome in Colon CancerClinical Cancer Research, 2011
- Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation CarriersCancer Epidemiology, Biomarkers & Prevention, 2011
- Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional ConsequencesJournal of Biological Chemistry, 2008
- Estrogen receptor α regulates expression of the breast cancer 1 associated ring domain 1 (BARD1) gene through intronic DNA sequenceMolecular and Cellular Endocrinology, 2007
- The BARD1 Cys557Ser Variant and Breast Cancer Risk in IcelandPLOS Medicine, 2006
- Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosisInternational Journal of Cancer, 2005
- Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal InstabilityMolecular and Cellular Biology, 2003
- Identification of a RING protein that can interact in vivo with the BRCA1 gene productNature Genetics, 1996